Efficacy of ruxolitinib in subcutaneous panniculitis-like T-cell lymphoma and hemophagocytic lymphohistiocytosis
Romain Lévy, Mathieu Fusaro, Frédéric Guèrin, A. Chetouani, Despina Moshous, Alain Fischer, Geneviève de Saint Basile, Fernando E. Sepulveda, Bénédicte Neven
Abstract
Key Points First evidence of ruxolitinib efficacy for subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic lymphohistiocytosis. Supporting rationale for ruxolitinib use, not more aggressive treatment, in this context, questioning this condition’s neoplastic nature.
Topics & Concepts
Hemophagocytic lymphohistiocytosisRuxolitinibMedicineLymphomaContext (archaeology)PanniculitisImmunologyDermatologyInternal medicineBone marrowBiologyDiseaseMyelofibrosisPaleontologyCutaneous lymphoproliferative disorders researchAutoimmune and Inflammatory Disorders ResearchLymphoma Diagnosis and Treatment